Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APX-115 in Type 2 Diabetes Mellitus and Diabetic Nephropathy
2019-004155-37Phase 2Completed
- Sponsor
- AptaBio Therapeutics Inc.
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis comparing APX-115 with Placebo (2 arms). Primary endpoint: Primary endpoint: change in UACR at Week 12. Started Mar 2020; status: completed.
02
Drugs
isuzinaxib
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on 2019-004155-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004155-37.